ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1606

One Year Real-World Effectiveness with Avacopan in Granulomatosis with Polyangiitis and Microscopic Polyangiitis in a Large Healthcare System
Abstract Number: 2178

Online Education Significantly Improved Rheumatologists’ Knowledge of the Diagnosis and Management of Sjögren’s Disease
Abstract Number: 0164

Online Patient Survey on the Impact of Extreme Weather Events on Autoimmune and Rheumatic Diseases
Abstract Number: 2701

Ophthalmic Manifestations of Relapsing Polychondritis
Abstract Number: 0253

Ophthalmology Screening for Asymptomatic Uveitis in Sarcoidosis Patients: A Single-Center Investigation
Abstract Number: 1894

Opioid Use Disorder Among Patients with Rheumatic Conditions in the All of Us Research Program: A Descriptive Analysis
Abstract Number: 1643

Optimizing Analyses of Chair Stand Test Outcome Data in the Multicenter Osteoarthritis Study: Exploration of Approaches to Handling Missing and/or Skewed Data with Performance-based Function Measures
Abstract Number: 1938

Optimizing Patient Outcomes: The Experience of a Multidisciplinary Rheumatology and Hand Surgery Clinic with Point-of-Care Musculoskeletal Ultrasound Integration
Abstract Number: 0183

Optimizing the Clinical Application of Rheumatology Guidelines Using Large Language Models: A Retrieval-Augmented Generation Framework Integrating EULAR and ACR Recommendations
Abstract Number: 2157

Optimizing the Diagnosis and Treatment of Kawasaki Disease-Associated Macrophage Activation Syndrome: A Clinical Cohort and Literature Analysis
Abstract Number: 0935

Oral Antibiotic Treatment Reduces Anxiety in a Murine Model of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Abstract Number: 1730

Oral glucocorticoid treatment for checkpoint inhibitor associated inflammatory arthritis do not affect progression free survival: a RADIOS Registry cohort study
Abstract Number: 1928

Oral Health in Patients with Rheumatic Diseases: A Pilot Quality Improvement Program
Abstract Number: 2622

Oral Microbiome Dysbiosis and Oral-gut Microbial Network Disruption in Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study
Abstract Number: 2418

ORF1p Expression Correlates with STING Activation and IFN Signatures in SLE Nonlesional Skin

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].